CRUSH PAD: Real-world Outcomes Following Use of the Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

Peripheral Arterial Disease Clinical Trial

Official title:

CTA_IIT_CRUSH PAD: Real-world Outcomes Following Use of the Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05145478
• Other study ID #: 2000031113
• Status: Recruiting
• Start date: December 1, 2021
• Est. completion date: June 1, 2026

Study information

• Verified date: January 2024
• Source: Yale University
• Contact: Kim Smolderen, PhD
• Phone: 203-737-7673
• Email: kim.smolderen[@]yale.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary goal of the study is to obtain effect size data on the use of Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with peripheral artery disease for a series of endpoints, including target lesion revascularization and health status, to enable future planning of comparative effectiveness research.

Description:

The primary objective of this study is to evaluate the generic health status outcomes and efficacy and safety outcomes following use of the Shockwave Intravascular Lithotripsy (IVL) technology in calcified common femoral lesions in patients with PAD seen in routine clinical practice. The main testable hypothesis is that the use of IVL is associated with a health status improvement that is equal or higher than the threshold of a minimally clinically important difference on the EQ5D. Preliminarily data will be derived for the primary endpoint target lesion revascularization to enable future planning of larger comparative effectiveness research. Secondary objectives of the study are to document procedural success following the use of IVL in common femoral lesions, disease stage change, as well as disease-specific health status in the real-world.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: June 1, 2026
• Est. primary completion date: June 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects presenting with claudication or CLI by Rutherford Clinical Category 2, 3, 4, 5, or 6 of the target limbs
• Subject is a suitable candidate for angiography and endovascular intervention per the latest clinical guidelines
• Patient is scheduled to undergo treatment with Shockwave Intravascular Lithotripsy (IVL) technology followed by standard of care treatment with DCB, BMS, DES at the physician's discretion. Angiographic Inclusion Criteria
• Target lesion that is located in a native, de novo common femoral artery
• Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate.
• Target lesion is =70% stenosis by investigator via visual estimate.
• Target lesion length is =50mm for lesions 70-99% stenosed. Target lesion can be all or part of the 50mm treated zone.
• Chronic total occlusion, lesion length is =50mm of the total =50 mm target lesion.
• Patient has open profunda femoris artery for the target leg, defined as no stenosis >50%.
• Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is =50mm in length; or extending for minimum of 20mm if lesion is <50mm in length.

Exclusion Criteria:

• Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Shockwave Medical Peripheral Lithoplasty® System as per Instructions for Use (IFU) or investigator's opinion.
• Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints.
• Cognitive impairment as documented in medical records
• Not speaking English or Spanish
• Currently a prisoner
• Pregnancy or nursing
• Estimated survival less than 12 months at the time of screening
• Prior history of CFA endarterectomy

Related Conditions & MeSH terms

• Chronic Limb-Threatening Ischemia
• Claudication
• Critical Limb Ischemia
• Ischemia
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• Shockwave Intravascular Lithotripsy (IVL)
Eligible patients with atherosclerotic lesions in the femoral artery who either have claudication or critical limb ischemia will receive endovascular treatment in addition to be treated with Shockwave Intravascular Lithotripsy (IVL) technology.

Locations

Country	Name	City	State
United States	Yale New Haven Health	New Haven	Connecticut

Sponsors (3)

Lead Sponsor	Collaborator
Yale University	Shockwave Medical, Inc., University Hospitals Cleveland Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Health Status	Health status will be measured using the disease-specific Peripheral Artery Questionnaire (PAQ). PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.	Baseline, 30 days and 6 months
Primary	Change in Generic Health Status	Generic Health Status will be measured using the EQ5D health status assessment. Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. Higher scores indicate more severe or frequent problems.	Baseline and 30 days
Primary	Change in Generic Health Status	Generic Health Status will be measured using the EQ5D health status assessment. Descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain & discomfort, Anxiety & depression), each of which has five severity levels that are described by statements appropriate to that dimension. Higher scores indicate more severe or frequent problems.	Baseline and 6 months
Primary	Rate of Procedural Success	Procedural success defined as residual stenosis =30% without flow-limiting dissection (= grade D) prior to DCB	Immediately post procedure
Secondary	Number of Patients Free from TLR	Freedom from clinically driven target lesion revascularization (TLR). Assessed at 30 days, 6 months and 12 months.	Up to 12 months
Secondary	Number of patients with new-onset MAEs	The composite of new-onset Major Adverse Events (MAEs) is comprised of: Need for emergency surgical revascularization of target limb, including CFA endarterectomy; Unplanned target limb major amputation (above the ankle); Symptomatic thrombus or distal emboli that require surgical, mechanical, or pharmacologic means to improve flow and extend hospitalization; Perforations that require an intervention, including bail-out stenting	Up to 12 months
Secondary	Rate of Periprocedural clinical success	Periprocedural clinical success as defined by residual stenosis =30% without flow-limiting dissection (= grade D) prior to DCB or stenting.	During admission, before discharge up to 48 hours
Secondary	Change in Clinical Success	Rutherford Category. Classification of PAD into acute and chronic limb ischemia associated by clinical symptoms. Evaluates patient's chronic limb pain and claudication by ABI/TBI. The category scale is from 0-6. The clinical interpretation of the scale is that a higher category indicates a worse condition.	Baseline and 30 days
Secondary	Change in Clinical Success	Rutherford Category. Classification of PAD into acute and chronic limb ischemia associated by clinical symptoms. Evaluates patient's chronic limb pain and claudication by ABI/TBI. The category scale is from 0-6. The clinical interpretation of the scale is that a higher category indicates a worse condition.	Baseline, 6 months and 12 months